Interaction of exercise training andn-3 fatty acid supplementation on postprandial lipemia

2007 ◽  
Vol 32 (3) ◽  
pp. 473-480 ◽  
Author(s):  
Tom R. Thomas ◽  
Ying Liu ◽  
Melissa A. Linden ◽  
R. Scott Rector
Keyword(s):  
Fatty Acid ◽  
Exercise Training ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Repeated Measures ◽  
Postprandial Lipemia ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Omega 3

The effect of combining omega-3 fatty acid (n-3 FA) supplementation and exercise training treatment on postprandial lipemia (PPL) has not been studied. The purpose of this study was to examine the interaction of n-3 FA and exercise training in attenuating PPL after a high-fat meal. Previously sedentary, overweight, subjects (n = 22; 12 women, 10 men, BMI 26.6 ±0.7 kg/m2) were randomly assigned to one of two treatment groups: n-3 FA supplementation alone (FO, n = 10) or n-3 FA supplementation plus exercise training (FO+ExTr, n = 12). Both groups consumed 4 g/d n-3 FA, and one group also exercise trained for 45 min/d, 5d/week of brisk walking and (or) jogging at 60% VO2 max. Before and after 4 weeks of treatment, subjects performed a baseline PPL and a PPL following a single session of exercise (ExPPL). PPL was assessed by triglyceride (TG) area under the curve (AUC) and peak TG response (TGpeak). A two-way analysis of variance (ANOVA) with repeated measures was used to compare results from treatments for baseline and exercise trials. FO alone reduced PPL and Ex PPL, and FO+ExTr attenuated the ExPPL response measured as total AUC and TGpeak. There was no significant main effect for group or group by time interaction for baseline PPL or ExPPL. Fasting high-density lipoprotein cholesterol (HDL-C) and HDL2-C (i.e., subfraction 2) concentrations were significantly increased in the FO+ExTr group after the treatments. These results suggest that n-3 FA supplementation reduced PPL in sedentary subjects. Exercise training has no interference or additive effects with n-3 FA supplementation in attenuating PPL, but combined treatments may be additive in raising high-density lipoprotein cholesterol.

scholarly journals APOE genotype affects black-white responses of high-density lipoprotein cholesterol subspecies to aerobic exercise training

Metabolism ◽  
2008 ◽  
Vol 57 (12) ◽  
pp. 1669-1676 ◽  
Author(s):  
Thomas O. Obisesan ◽  
Robert E. Ferrell ◽  
Andrew P. Goldberg ◽  
Dana A. Phares ◽  
Tina J. Ellis ◽  
...  
Keyword(s):  
Exercise Training ◽  
High Density Lipoprotein ◽  
Aerobic Exercise ◽  
High Density Lipoprotein Cholesterol ◽  
Apoe Genotype ◽  
Density Lipoprotein ◽  
High Density ◽  
Aerobic Exercise Training ◽  
Lipoprotein Cholesterol

Combined Detection of Free Fatty Acid (FFA) and High-Density Lipoprotein Cholesterol (HDL-C) is a Promising Pretreatment Biomarker for Predicting the Overall Prognosis (OS) of Neuroendocrine Tumours (NETs) in the Colorectum: A Case-Control Study.

2021 ◽  
Author(s):  
Bin Zhu ◽  
Dan Wu ◽  
Yuanyuan Yang ◽  
Pingli Yu ◽  
Haobo Huang ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Free Fatty Acid ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Neuroendocrine Tumours ◽  
Tumour Size ◽  
Density Lipoprotein ◽  
High Density ◽  
Apolipoprotein A1 ◽  
Lipoprotein Cholesterol

Abstract Purpose The aim of the study was to evaluate the prognostic value of free fatty acid (FFA) and high-density lipoprotein cholesterol (HDL-C) in predicting colorectal neuroendocrine tumours (NETs). Methods One hundred patients with pathologically diagnosed colorectal NETs in 2011-2017 were enrolled, and the levels of FFA, HDL-C, low-density lipoproteincholesterol (LDL-C), triglycerides (TGs), cholesterol (CHOL), apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) between colorectal NET patients and healthy controls matched by age and sex were compared. In addition, the association of clinicopathological characteristics and follow-up data with FFA and HDL-C was analysed. Results FFA was overexpressed (0.55±0.23 vs. 0.48±0.11, P= 0.006) and HDL-C was underexpressed (1.31±0.41 vs. 1.41±0.29, P=0.046) in colorectal NETs. FFA ≥0.52 mmol/L predicted lymph node metastasis (LNM) (χ2 = 5.964, P=0.015), and HDL-C ≤1.0 mmol/L predicted tumour size ≥2 cm (χ2 = 5.647, P=0.017). No significant association was found between FFA and tumour size (P=0.142) or HDL-C and LNM (P=0.443). FFA ≥0.52 mmol/L (χ2 = 6.016, P=0.014) and HDL-C ≤1.0 mmol/L predicted worse overall survival (OS) (χ2 = 5.488, P=0.019). FFA ≥0.52 mmol/L in combination with HDL-C ≤1.0 mmol/L predicted an even worse prognosis in terms of OS (χ2 = 4.818, P=0.028). Conclusion FFA ≥0.52 mmol/L and HDL-C ≤1.0 mmol/L were promising cut-off values in predicting LNM, tumour size and worse OS in colorectal NETs.

Postprandial Lipemia in Postmenopausal Women with High Fasting High-Density Lipoprotein Cholesterol

2006 ◽  
Vol 331 (1) ◽  
pp. 10-16 ◽  
Author(s):  
Genovefà D. Kolovou ◽  
Katherine K. Anagnostopoulou ◽  
Klelia D. Salpea ◽  
Nektarios D. Pilatis ◽  
Georgia Grapsa ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
Postmenopausal Women ◽  
High Density Lipoprotein Cholesterol ◽  
Postprandial Lipemia ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol

scholarly journals Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training

2006 ◽  
Vol 185 (1) ◽  
pp. 65-69 ◽  
Author(s):  
Gualberto Ruaño ◽  
Richard L. Seip ◽  
Andreas Windemuth ◽  
Stefan Zöllner ◽  
Gregory J. Tsongalis ◽  
...  
Keyword(s):  
Exercise Training ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Apolipoprotein A1 ◽  
Lipoprotein Cholesterol

Responses of Blood Lipids to Aerobic, Resistance, and Combined Aerobic with Resistance Exercise Training: A Systematic Review of Current Evidence

Angiology ◽  
2008 ◽  
Vol 60 (5) ◽  
pp. 614-632 ◽  
Author(s):  
Konstantinos Tambalis ◽  
Demosthenes B. Panagiotakos ◽  
Stavros A. Kavouras ◽  
Labros S. Sidossis
Keyword(s):  
Exercise Training ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Combined Exercise

This review considers the effectiveness of aerobic exercise training with different intensities (moderate and high) as well as the type of exercise (aerobic, resistance, and combined aerobic with resistance) in altering the blood lipids. We reviewed various trials via a systematic search of PubMed, published reviews, and references from original articles. We selected studies that involved aerobic and/or resistance and/or combined exercise training in healthy adults over a limit of 12 weeks and had examined the response of training to one or more of the following: triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. We selected a total of 84 studies, 58 were randomized controlled trials. Comparisons between intensities of aerobic exercise programs resulted in favorable effects only for high intensity. The most frequently observed alteration was an increase in the high-density lipoprotein cholesterol, whereas reductions in triglycerides, total cholesterol, and low-density lipoprotein cholesterol appeared less often. Moreover, the evidence of the positive effect of resistance exercise marks out a trend mainly for the low-density lipoprotein cholesterol levels, whereas for combined exercise, results extracted from a short list of published studies show improvements in values of both the high-density lipoprotein cholesterol and the low-density lipoprotein cholesterol. High-intensity aerobic training results in improvement in high-density lipoprotein cholesterol. For resistance and combined exercise, the results are inconsistent. The heterogeneity between the types of exercise did not allow reliable comparisons.

Relative Efficacy of Antilipemic Agents in Non–High-Density Lipoprotein Cholesterol Reduction

2012 ◽  
Vol 25 (4) ◽  
pp. 447-456
Author(s):  
Jennifer Santee ◽  
Cameron Lindsey ◽  
Heather Pace
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Information Service ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Percentage Reduction ◽  
Omega 3 ◽  
Reductase Inhibitors ◽  
Reported Data

The investigators sought to summarize the percentage reduction in non–high-density lipoprotein cholesterol (non-HDL-C) achieved with various antilipemic regimens and to determine whether certain antilipemic regimens have been proven more effective in lowering non-HDL-C. A search of MEDLINE, International Pharmaceutical Abstracts, and Iowa Drug Information Service Database from 1970 to May 2011 was performed. Criteria were used to exclude studies not published in English, studies with methodology limitations, and studies with variables that may affect efficacy beyond the antilipemic agent administered. Only randomized, controlled trials comparing medications approved by the Food and Drug Administration were reviewed to determine whether significant differences in percentage reduction in non-HDL-C had been observed between different medication regimens. A total of 51 trials reported data that could be used to determine the range of percentage reduction in non-HDL-C achieved by select antilipemic regimens. Of these 51 trials, 38 provided head-to-head comparisons of antilipemic regimens. Rosuvastatin and atorvastatin are the most potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in lowering non-HDL-C. Adding ezetimibe, fibric acid derivatives, and omega-3 fatty acids to antilipemic monotherapy may result in further reduction in non-HDL-C. Subjects with certain characteristics (eg, nonwhite) were not prevalent in these studies.

Sign in / Sign up

Export Citation Format

Share Document